3900 Gantz Rd
50 articles about Forge Biologics
Myrtelle Inc. and Forge Biologics today announced a manufacturing partnership that will advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials for patients with autosomal recessive deafness 8 (DFNB8).
Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients
Forge Biologics today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.
This week was rife with Series financings, which channeled money into innovative treatments for immune diseases and cancers, genomic treatments and precision healthcare.
Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has raised $90 million in a Series C financing, bringing its total funding raised to date to $330 million.
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Christina Perry, Senior Vice President of Finance & Investor Relations, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, in New York, NY.
Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that Maria Escolar, M.D., Chief Medical Officer, will present preliminary clinical data on the treatment of its first patient in the RESKUE Phase 1/2 clinical trial for FBX-101,
Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.
Forge Biologics Forms Independent Scientific and Manufacturing Advisory Board with Panel of Gene Therapy Leaders
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today the formation of an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development.
Forge Biologics Announces 7 Presentations at the Upcoming Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Forge Biologics announced today that it will deliver seven presentations during the upcoming American Society of Gene and Cell Therapy’s (ASGCT) 25th Annual Meeting, taking place May 16-19, 2022, in Washington, D.C.
Forge Biologics to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Forge Biologics to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March.
Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
Ray Therapeutics and Forge Biologics, announced a manufacturing partnership that will advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001, into clinical trials for patients with retinitis pigmentosa.
Forge Biologics announced today 2022 manufacturing expansion plans to meet the growing demand for gene therapy manufacturing.
Forge Biologics to Present at 40th Annual J.P. Morgan Healthcare Conference.
Forge Biologics announced today that Timothy J. Miller, Ph.D., Forge’s CEO, President, and Co-Founder, will deliver a company presentation at the Jefferies Gene Therapy / Editing Summit on Thursday, October 28, at 12:30 p.m. ET.
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President and Co-Founder, will discuss Forge’s robust AAV manufacturing solutions, proprietary technology advancements, and clinical development during a company presentation at Cell & Gene Meeting on the Mesa on October 12 at 5:00 p.m. PT.
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
Solid Biosciences Inc. and Forge Biologics announced a partnership to advance the development and manufacturing of SGT-003, Solid’s next generation gene therapy program for Duchenne.
Forge Biologics Announces Regulatory Updates from FDA and EMA, Accelerating Manufacturing and Clinical Trial Momentum
Forge Biologics today announced that it has received additional designations and regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), advancing the manufacturing capabilities for its own and clients’ AAV gene therapies.
Forge Biologics Announces Key Hires in CDMO Operations and Medical Affairs, Company Presentations at World Orphan Drug Congress
Forge Biologics announced today the expansion of its leadership team with two key hires in process development and medical affairs.
GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership
GentiBio, Inc. announced a strategic development and manufacturing partnership today to advance GentiBio’s unique immune tolerance platform.